Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Capricor Therapeutics, Inc.

Report topline data from HOPE-3 (Cohort A)

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
11 Dec 2023
Due
31 Dec 2024
Checked
1 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“reporting topline data from HOPE-3 (Cohort A) in the fourth quarter of 2024”

What we found

Evidence strength A What the grades mean

The company did not report topline data for HOPE-3 (Cohort A) by the end of 2024; a subsequent filing indicates data is expected in the fourth quarter of 2025.

  • A
    Capricor Therapeutics, Inc. 10-Q filed 2025-11-10 Regulatory filing · published 10 Nov 2025 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint f4ba9fa17cf4
    “Topline HOPE-3 data are expected in the coming weeks (fourth quarter of 2025)” ✓ confirmed on the page

Market reaction: the shares moved -2.9% against the S&P 500 over the three sessions around the disclosure (7 Nov 2025 to 12 Nov 2025). What this measures

Checked 1 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Report
Deliverable
HOPE-3 (Cohort A) topline data
Language
Aspirational (“aims”, “intends”)
In the company’s control
High
Specificity
High
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
  4. Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2023-CAPR-002539 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.